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Fig. 1. Rilpivirine concentrations with and without bocepre-
vir. Median pharmacokinetic profile and range of rilpvirine in
patients treated with (black) and without (gray) boceprevir.In 2012, hepatitis C virus (HCV) protease inhibitors
were the first direct-acting antivirals that led to an
improved treatment response when combined with
peginterferon-alfa and ribavirin for the treatment of
HCV infections. However, when used in HIV-positive
patients, treatment with direct-acting antivirals is more
complicated regarding possible drug–drug interactions
(DDIs) with combination antiretroviral therapy. The
nonnucleoside reverse transcriptase inhibitor rilpivirine
is a CYP3A4 substrate and therefore potentially
interacts with boceprevir, a CYP3A4 inhibitor. Based
on a healthy volunteer DDI study, exposure to
rilpivirine increased by 39% when given together with
boceprevir [1]. This increased exposure did not lead to
clinically significant corrected QT (QTc) prolongation
during short-term administration in the healthy
volunteers. Therefore, the product label of boceprevir
states that the drug can be coadministered with
rilpivirine; this also holds for other HCV protease
inhibitors and CYP3A4 inhibitors, such as telaprevir
and simeprevir [1–3].
We performed a subanalysis within the Dutch acute HCV
in HIV study to describe the pharmacokinetic interaction
between boceprevir and rilpivirine in HIV/HCV-
positive patients and the possible effects on QTc-interval
prolongation [4].
In the Dutch acute HCV in HIV study, 57 HIV-positive
patients were treated for an acute HCV infection with
12 weeks of weight-based pegylated interferon-alfa,
ribavirin, and boceprevir 800mg thrice daily [5]. In this
substudy, patients treated with rilpivirine 25mg daily
combined with two nucleos(t)ide reverse transcriptase
inhibitors were included. Patients were instructed to take
rilpivirine together with at least a 500 kcal meal. Blood
samples were taken before the start of HCV therapy (T0)
and at week 4 of therapy (T4) during the elimination
phase of the drug (t¼ 4–24 h after administration).
Concurrently, with the blood draw, a single 12-lead ECG
was recorded in all participants at T0 and T4. Heart rate
QTc was calculated using Bazett’s formula. Rilpivirine
plasma concentrations were analyzed by a validated
reversed-phase ultra-performance liquid chromato-
graphic method with ultraviolet detection (linear
calibration range (0.0063–3.75mg/l). Concentration-
time data were analyzed using nonlinear mixed-effect
modeling (NONMEM version 7.2; ICON, Dublin,
Ireland). The effect of boceprevir and alanine amino- Copyright © 2016 Wolters Kluwe
ISSN 0269-9370 Copyright Q 2016 Wolters Ktransferase (ALT) on rilpivirine apparent clearance
(CL/F) was evaluated. Area under curve (AUC)0–24 h
was calculated using individual estimations for CL/F and
dose. The correlation between AUC0–24 h and QTc time
was analyzed using linear regression.
Twelve male patients (11/12 white people) were
included. Median age was 38 years [interquartile range
(IQR) 33–43]. Patients had a median ALT of 126U/l
(IQR 29–198) with no signs of liver failure at T0 and
their median ALT at T4 was 36U/l (IQR 28–39). In all
patients, the HIV viral load was fully suppressed at both
time points. One out of 12 patients had concomitant
medication potentially influencing the rilpivirine metab-
olism or QTc time (acetylsalicylic acid 80mg daily,
prasugrel 10mg daily, pravastatin 40mg daily, perindopril
2mg daily).
Median rilpivirine concentration at T0 and T4 was 0.16
and 0.26mg/l, respectively. In the individual patients, the
absolute rilpivirine concentration increased at T4 from
þ0.01mg/l (8%) to þ0.10mg/l (63%), when measured
at the same time point after intake. Pharmacokinetics of
rilpivirine were described using a one-compartment
model with fixed values for the absorption rate (ka¼ 0.7/
h) and volume of distribution (Vd¼ 152 l) based on the
literature. CL/F decreased from 7.2 to 3.8 l/h when
patients were treated with boceprevir (relative SE 14%,
P< 0.005). In the simulated pharmacokinetic profile, a
clear decrease in CL/F and AUC0–24 h is seen (Fig. 1).r Health, Inc. All rights reserved.
luwer Health, Inc. All rights reserved. 529
530 AIDS 2016, Vol 30 No 3This DDI explained 34% of the variability in CL/F. The
remaining variability of CL/F was 44% (RSE 13%). No
significant correlation between ALT and CL/F was seen.
Measured QTc intervals were not correlated with the
calculated rilpivirine AUC0–24 h. Patients without boce-
previr had a median rilpivirine AUC0–24 h of 3.8mg/l/h
with a corresponding QTc interval of 382ms (range
355–425ms) and patients treated with boceprevir had a
median rilpivirine AUC0–24 h of 6.5mg/h/l and a
corresponding QTc interval of 384ms (range 349–
425ms).
The rilpivirine AUC0–24 h values seen in the patients
without boceprevir treatment were comparable to values
previously described [6]. In contrast, the increase in
rilpivirine AUC0–24 h (71%) that we found in this study is
higher than previously described in healthy volunteers
(39%) [1]. This suggests that data from healthy volunteers
cannot be translated one on one to HIV-infected patients.
This is the first analysis of rilpivirine DDI interactions
with boceprevir in HIV-infected patients. More effective
interferon-free treatment options have recently become
available for the treatment of chronic HCV. However,
given the very high costs, their availability is currently
limited to a very small number of patients. Therefore, it is
likely that boceprevir will continue to be used for some
time. We show that it can be safely combined with
rilpivirine.Acknowledgements
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DOI:10.1097/QAD.0000000000000950Uncontrolled hepatitis delta virus infection after initial suppression on tenofovir in a HIV/HBV-coinfected
patientHeptitis delta virus (HDV) infection affects 10-15% of
HIV/hepatitis B virus (HBV)-coinfected individuals in
Europe and can lead to severe hepatic inflammation [1].
Although interferon a remains the mainstay of HDV
therapy [2], the potential efficacy of tenofovir disoproxil
fumarate (TDF) in reducing HDV viral replication
in HIV-infected patients has been recently suggested[3]. In a recent publication, James et al. described the first
case of HBVand HDV clearance in a patient treated with
TDF [4].
A 38-year-old man fromMali was diagnosed with HIV-1
in our clinic in October 2008. He had nine CD4þ cells/
ml (1%) and an HIV viral load of 107 000 copies/ml.ealth, Inc. All rights reserved.
Correspondence 531He was hepatitis B surface antigen (HBsAg)-positive,
hepatitis B envelope antigen-negative had an initial HBV
viral load of 1 125 347 IU/ml and HBV sequencing
showed a genotype E. He was also coinfected with HDV
with a baseline viral load of 300 000 copies/ml. He had
elevated liver enzymes including an alanine aminotrans-
ferase (ALT) of 250U/l and an aspartate aminotransferase
of 150U/l. The patient experienced a rapid virological
suppression of HIV, HBV, and HDV within 3 months
after initiation of a TDF-containing antiretroviral
therapy (ART) (Fig. 1). During the following 2.5 years,
theHIV,HBV, andHDVviral loads remained suppressed,
his transaminases were in the normal range, and the
CD4þ cell count increased to 406 cells/ml (14%). In
October 2013, he travelled to Mali and interrupted his
ART. As he came back 9 months later, his CD4þ cell
count had dropped to 131 cells/ml (7%), he had high
HIV, HBV, and HDV viral loads, and signs of active
hepatitis with transaminases five times above the upper
limit of the norm. He was prescribed a new TDF-
containing ART regimen, according to HIV resistance
testing. Although the HIV and HBV viral loads were
suppressed to undetectable levels 4 months later, he
maintained high-level HDV replication (Fig. 1). Trans-
aminases remained elevated, with ALT levels mirroring
changes in HDV viral load until the last measurement in
June 2015. Quantitative HBsAg levels dropped from
12 252 to 6 586 IU/ml between treatment initiation in
2008 and the time of treatment interruption in 2013. At
reinitiation in 2014, the level had reached 46 288 IU/ml
and had only dropped to 10 122 IU/ml 10 months
later. Copyright © 2016 Wolters Kluwe
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Fig. 1. Antiretroviral therapy history and laboratory measureme
darunavir; DTG, dolutegravir; EFV, efavirenz; FTC, emtricitabine; H
boosted lopinavir; TDF, tenofovir disoproxil fumarate.In this HIV/HBV/HDV-coinfected patient, rapid and
sustained virological suppression of all three viruses as well
as normalization of transaminases were obtained with a
TDF-containing regimen. However, the same outcome
was not achieved after TDF reinitiation following a
9-month treatment interruption. Despite rapid virologi-
cal suppression of HIV and HBV, the HDV viral load
remained very high 10 months later. Interestingly, ALT
levels remained elevated and fluctuated according to
HDV RNA levels.
Several hypotheses can be raised to explain the different
responses to TDF in our patient. First, he started his first
course of ART in a state of severe immune suppression
with fewer than 10 CD4þ cells/ml, whereas his cellular
immunity was less impaired at the time of ART
reinitiation in 2014. Thus, it could be postulated that
the recovery of cellular immunity rather than the effect of
TDF on HBV replication was the main reason for control
of HDV replication during the first treatment episode. It
is plausible that the immune recovery effect was less
pronounced after the short treatment interruption in
2013. Another possibility is that immune escape variants
emerged over time and hindered the immunological
control of HDV replication in the second treatment
episode.
This case shows the potential benefit of long-term
TDF treatment for HDV infection, but also underlines
the strong link between HDV replication and liver
inflammation. Treatment interruptions in HIV/HBV
and HIV/HBV/HDV-coinfected patients can lead tor Health, Inc. All rights reserved.
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532 AIDS 2016, Vol 30 No 3severe, potentially fatal hepatitis flares [5]. The
mechanisms of action of TDF on HDV replication
and the predictors of treatment success remain largely
unknown. Thus, large, prospective studies are needed to
better understand the potential role of TDF in the
treatment of HDV infection.Acknowledgements
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DOI:10.1097/QAD.0000000000000972Favorable outcome of severe human herpes virus-6
After primary infection, the ubiquitous T-lymphotropicencephalitis in an HIV-infected patientHerpesviridae human herpes virus-6 (HHV-6) establishes a
life-long latent infection in most adults. In immuno-
compromised patients, HHV-6 reactivation may lead to
various clinical syndromes including potentially life-
threatening limbic encephalitis that has been mostly
described in hematopoietic stem cell transplant recipients.
Here, we report the successful management of severe
HHV-6 encephalitis in an HIV-infected patient.
A 41-year-old HIV-1-infected male presented to our
department on 12 February 2014 for an acute confusional
state. On 20 January 2014, he was asymptomatic with a
CD4þT-cell count of 44 cells/ml (4%) and a plasma HIV-
1 viral load of 5 log10 copies/ml. An antiretroviral therapy
(ART) based on ritonavir-boosted atazanavir, tenofovir
and emtricitabine together with cotrimoxazole chemo-
prophylaxis was started. On admission, clinical examin-
ation revealed confusion, periods of loss of contact, and
a bilateral Babinski sign without neurological focalization.
Brain MRI showed on fluid-attenuated inversion
recovery (FLAIR)-weighted images confluent signal
hyperintensities in the corpus callosum and the adjacent
white matter (Fig. 1a and b). Electroencephalography was
suggestive of seizures. Cerebrospinal fluid (CSF) cyto-
logical and biochemical analysis were normal. PCR on
CSF were positive for HIV-1 (4.1 log10 copies/ml) and
HHV-6 (5 log10 copies/ml), and negative for herpes
simplex virus varicella-zoster virus Epstein–Barr virus(EBV), cytomegalovirus (CMV) enterovirus and John
Cunningham virus. Direct staining, antigen titer, cultures
and PCR for mycobacteria, Toxoplasma and Cryptococcus
on CSF were negative. Blood CD4þ T-cell count was
137 cells/ml (13%), whereas plasma HIV-1 viral load had
dropped to 3.8 log10 copies/ml. PCR on whole blood
were positive for CMV (3.1 log10 copies/ml), EBV
(4.8 log10 copies/ml) and HHV-6 (4.2 log10 copies/ml).
Serology for syphilis was negative. A diagnosis of HHV-6
encephalitis was made. ARTwas continued and a therapy
based on i.v. ganciclovir 5mg/kg bid associated with oral
leviteracetam 500mg bid and lacosamide 100mg bid was
started. The patient gradually improved. At 3 weeks,
HHV-6 viral load in the CSF decreased below the
detection threshold, and ganciclovir was switched to oral
valganciclovir 900mg bid before the patient was
discharged home with a complete clinical recovery
(Fig. 1e). On May 2014 brain MRI showed only subtle
residual hyperintensity of the corpus callosum (Fig. 1c
and d), which disappeared in September 2014. HHV-6
viremia remained stably detectable in blood from
February 2014 to January 2015 (mean 3.5 0.4
log10 copies/ml) and then decreased below the detection
threshold (3 log10 copies/ml). PCR for HHV-6 per-
formed on hair follicles in November 2014 was negative.
Blood PCR for CMV remained undetectable from
March 2014. Antiepileptic drugs were stopped in August
2014. Valganciclovir was tapered to 900mg/day in
December 2014 and stopped in July 2015. By Septemberealth, Inc. All rights reserved.
 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
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Fig. 1. (a–d) Brain MRI: coronal (a, c) and sagittal (b, d) reformatted FLAIR images. Initial images (a) and (b) demonstrate
confluent signal hyperintensities in the corpus callosum and the adjacent white matter that significantly decrease after 3 months (c
and d). At that time, only subtle residual hyperintensity can be depicted on the sagittal view at the anterior aspect of the corpus
callosum. No enhancement of the lesions was observed on postgadolinium T1-weighted images (not shown). (e) Course of whole
blood HHV-6 viral load, plasma HIV-1 viral load, and CD4þ T-cell count and therapy. Of note, undetectable viral load for HHV-6
means below the detection threshold.
534 AIDS 2016, Vol 30 No 32015, the patient was fully independent without any
neurological abnormalities and had an undetectable
HIV-1 viral load and a CD4þ T cell count of
365 cells/ml (18%) on ART.
The central nervous system (CNS) is considered as one
site of persistence of HHV-6 following primary infection
[1–3]. Immunosuppression may allow HHV-6 reactiva-
tion and the emergence of manifestations that include
encephalitis, hepatitis, pneumonitis, and bone marrow
suppression. Encephalitic syndromes related to HHV-6 in
transplanted patients are mostly represented by limbic
encephalitis with confusion, memory dysfunction, con-
sciousness disturbance and seizures, together with
hippocampus and amygdala lesions on brain MRI.
However, involvement of limbic structures outside of
the medial temporal lobe has been described [4]. Three
cases of HHV-6 encephalitis in HIV-infected patients
have been reported, all with a fatal issue [5–7]. HHV-6
DNA was only rarely detected in the CSF of immu-
nocompromised HIV-infected patients, and relationship
between HHV-6 replication and encephalitis is debated
[8,9]. Because of the ubiquitous presence of latent
HHV-6 infection in adults, separating latent from active
HHV-6 infection is indeed crucial. In immunocompro-
mised patients with suggestive neurological and brain
MRI manifestations, as in our patient, the detection of
HHV-6 DNA in CSF is however key to consider the
diagnosis of active CNS infection. Moreover, in our
patient, the negativity of the PCR for HHV-6 performed
on hair follicles argued against a chromosomal integration
of HHV-6 [10]. No consensus on therapeutic manage-
ment of HHV-6 encephalitis has been formulated, and
ganciclovir, foscarnet or cidofovir has been used alone or
in combination. In our patient, 3 weeks of ganciclovir
until drastic reduction of CSF HHV-6 viral load followed
by prolonged valgangiclovir were well tolerated and
associated with a long-term favorable outcome. The
ART-induced immune recovery associated with a
possible unmasking immune reconstitution inflammatory
syndrome in this patient might have also favored the
control of HHV-6 reactivation [11–14].Acknowledgements
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